All News

AI offers many benefits in health professions by efficiently handling time-consuming tasks crucial for patient care.

The study is the first of 5 studies co-published by AYR Wellness and LECOM and showcases improvements in physical, social, and mental well-being with minimal AEs.

The latest FDA approval paves the way for expanded use of GLP-1 receptor agonists in patients without diabetes.

The extension trial of atogepant demonstrated an 8.5-day improvement of monthly migraine days at weeks 13 through 16 and no new safety signals were observed.

The 5-in-1 meningococcal ABCWY vaccine candidate has an assigned Prescription Drug User Fee Act action date of February 14, 2025.

Erectile dysfunction medications started the shift, then coinsurance, deductibles, and the COVID-19 pandemic accelerated it.

The authors note that additional research needs to be conducted to confirm whether the findings are consistent in adult patients.

Sa’ed Al-Olimat, PharmD, co-founder of the Psychedelic Pharmacists Association, discussed the future of psychedelic medicines and the unique ethical challenges they present.

The campaign for National Stress Awareness Month in April is under way.

Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some common challenges pharmacists may be facing when looking to operationalize bispecifics at their facilities.

Investigators also found that the pneumococcal conjugate vaccine 13 protected against nasopharyngeal carriage in children and provided some indirect protection for adults.

Although the vaccine has not yet been tested in humans, it demonstrated 100% efficacy in protecting primates who were injected with human Marburg virus disease.

There was no difference observed between adalimumab (Humira; AbbVie) and adalimumab-aacf (Idacio; Fresenius Kabi) for those who switched to the biosimilar.

Investigators found that the individuals’ peak cognitive performance coincided with glucose levels that were slightly above the normal range.

SGLT-2 inhibitors reduce cardiovascular deaths, heart failure hospitalizations, hyperkalemia, and decline of renal function in patients with HFrEF.

Investigators added that additional randomized trials are still needed to confirm the benefits of traditional Chinese medicine, either with or without conventional therapies.

The impact pharmacist-led research on oncology pharmacy practice in the field of oncology is undeniable.

Opill is a nonprescription, progestin-only contraceptive pill, with nearly 50 years of use and data supporting the safety and effectiveness of progestin-only pills.

Bristol Myers Squibb will also present findings on apixaban (Eliquis) at the American College of Cardiology Annual Scientific Session and Expo.

Pandemic-related growing pains were common within health care, bringing unique challenges for health systems.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

Treatment with LYT-200 is currently being assessed in a phase 1/2 adaptive design trial in advanced/metastatic solid tumors and in a phase 1b clinical trial.

In this NCCN session, James M. Foran, MD, described the different FLT3 inhibitors that are available for FLT3-mutated AML, as well as considerations for the future.

In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.

The designation was granted based on overall survival data from an ongoing randomized phase 2 clinical trial.

In addition to oral administration, patients with partial-onset seizures can now take the antiseizure medication via a nasogastric tube if the tablet is crushed and mixed with water.

Both dual primary endpoints—progression-free survival and overall survival—were met with durvalumab.

The pharmacist integration model filled in gaps in care that appeared to positively affect MIPS and PCMH quality measures.

Jonathan Levitt, Esq, discusses legislation and legal action taken to rein in pharmacy benefit managers’ DIR fees.